Wire
Pharming Says European Commission Grants Marketing Authorization to Joenja
Pharming Group (PHAR) said late Friday the European Commission has granted marketing authorization to Joenja for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and older.Joenja is the first approved treatment in the European Union, the company said, expecting the first European launch in Germany in Q3 of 2026.Price: $12.78, Change: $-0.03, Percent Change: -0.23%
$PHAR
